Is FDA breakthrough therapy really valuable? image

Genet, April 13, 2018
Liu Xuan Tong, quoting Jonathan J. Darrow (Student Fellow Alumnus)


Read the Full Article

From the article:

In the recent New England Journal of Medicine, articles published by Harvard University's Jonathan Darrow, Jerry Avorn, and Aaron Kesselheim point out many of the issues arising from the "breakthrough therapies" of the US FDA and believe that reforms are needed; however, In this way, the FDA will still stick to its original position. 

Read the full article here!

health law policy pharmaceuticals